세계의 무표지 검출 시장 : 시장 규모, 점유율, 동향-제공별, 기술별, 용도별, 예측(-2029년)

The global label-free detection market is projected to reach USD 747 million by 2029 from USD 515 million in 2024, at a CAGR of 7.7% during the forecast period of 2024 to 2029. The growth of the Label-free detection market has been significantly driven by its increasing adoption among pharmaceutical and biotechnology companies for drug discovery application, increasing R&D investment by key players for the development and launch of innovative product and continuous advancements in label-free detection technologies. However, high instrument costs and the technical limitations of label-free detection are restraining market growth.

"The biosensor chips segment under consumables segment accounted for the largest share by offering in 2023."

In 2023, the biosensor chips segment under consumables segment accounted for the largest share by offerings in the global label-free detection market. Biosensors are valuable instruments in the domains of biochemistry and biomedical engineering, as they offer a means of detecting a range of analytes. Label-free biosensors are currently popular in proteomics and biomolecular interaction research because the transducer can detect the chemical or biological agent without the need for dyes, enzymes, or radiolabels. Many tiny compounds are typically found via chromatographic techniques, which are typically expensive, large, and need specialized knowledge. Biosensors provide a quicker and less expensive option. Biosensors offer several benefits over traditional techniques for detecting tiny molecules, such as the ability to monitor in real-time, their high specificity, quick reaction times, minimal need for organic solvents and sample handling, portability, compact design, and simple operation.

"The US has continued to dominate the label-free detection market during the forecast period of 2024-2029."

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, demand for label-free detection solutions is predicted to rise in the next years. Because of improved infrastructure, government assistance, and private financing, the country boasts a very developed R&D market. This advances creative and sophisticated research technologies. With label-free detection, which offers reduced turnaround time, and is energy-efficient and provides reliable results, with in a span of time, pharmaceutical companies in the US are actively collaborating in the creation of new reagent and test assays and using it. These elements help the global label-free detection industry to expand.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Danaher Corporation (US)

Sartorius AG (Germany)

Waters Corporation (US)

REVVITY, INC. (US)

Ametek, Inc. (US)

Horiba, Ltd. (Japan)

Spectris (UK)

Corning Incorporated (US)

Agilent Technologies, Inc. (US)

Shimadzu Corporation (Japan)

Hitachi High-Tech Corporation (Japan)

Attana AB (Sweden)

Bruker Corporation (US)

Bio-Rad Laboratories (US)

ENDRESS+HAUSER Group Services AG (Switzerland)

Becton, Dickinson and Company (US)

Nanotemper Technologies GmBH (Germany)

Affinite Instruments (Canada)

Biosensing Instrument (US)

Unchained Labs.(US)

BioNavis Ltd. (Finland)

Gator Bio (US)

Carterra, Inc. (US)

Nicoya Lifesciences Inc., (Canada)

BiOptix Analytical LLC (US)

Plexera Bioscience (US)

XanTec bioanalytics GmbH (Germany)

BMG Labtech (Germany)

RedShift BioAnalytics, Inc. (US)

lino Biotech AG (Switzerland)

Research Coverage:

This research report categorizes the label-free detection market by offering (Instruments, Consumables (Biosesor Chips, Microplates, Reagents & Kits), Software & Services), by Technology (Surface Plasmon Resonance, Differential Scanning Calorimetry, Bio-layer Interferometry, Isothermal Titration Calorimetry and Other Technologies), by Application (Binding Kinetics, Binding Thermodynamics, HIT Confirmation, Lead Generation, Endogenous Receptor Detection, and Other Application) by end user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organization, and Other End Users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Label-free detection market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the Label-free detection market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall label-free detection market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Technological advancements in label-free detection, Growing academic-industrial partnerships for drug discovery programs, High sensitivity of label-free technologies, Increasing R&D investments in biotechnology and pharmaceuticals), restraints (High cost of instruments, Technical complexity), opportunities (Growing life sciences research in emerging economies, Rising demand for label-free detection technologies in point of care and portable devices for rapid and on-site analysis in various industry, Increased focus on biomarker discovery), and Challenges (Sample complexity and interference, Stringent regulatory approval process) influencing the growth of the market).
• Product Development/Innovation: Detailed insights on newly launched products of the label-free detection market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the label-free detection market
• Competitive Assessment: Danaher Corporation (US), Sartorius AG (Germany), Waters Corporation (US), Agilent Technologies, Inc. (US), Corning Incorporated (US), REVVITY, INC. (US), Ametek, Inc. (US), Horiba, Ltd. (Japan), Spectris (UK), Shimadzu Corporation (Japan), Hitachi High-Tech Corporation (Japan), Attana AB (Sweden), Bruker Corporation (US), Bio-Rad Laboratories (US), ENDRESS+HAUSER Group Services AG (Switzerland), Becton, Dickinson and Company (US), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 MARKET STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY RESEARCH
  • 2.1.2 PRIMARY RESEARCH
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 MARKET LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LABEL-FREE DETECTION MARKET OVERVIEW
• 4.2 NORTH AMERICA: LABEL-FREE DETECTION MARKET SHARE, BY OFFERING AND COUNTRY (2023)
• 4.3 ASIA PACIFIC: LABEL-FREE DETECTION MARKET, BY END USER & COUNTRY (2023)
• 4.4 LABEL-FREE DETECTION MARKET SHARE, BY END USER, 2023
• 4.5 LABEL-FREE DETECTION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Technological advancements
    • 5.2.1.2 Growing academic-industrial partnerships for drug discovery programs
    • 5.2.1.3 High sensitivity of label-free technologies
    • 5.2.1.4 Increasing R&D investments in biotechnology and pharmaceuticals
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of instruments
    • 5.2.2.2 Technical complexity
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing life science research in emerging economies
    • 5.2.3.2 Rising demand for label-free detection technologies in point-of-care and portable devices for rapid and on-site analysis in various industries
    • 5.2.3.3 Increased focus on biomarker discovery
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Sample complexity and interference
    • 5.2.4.2 Stringent regulatory approval process
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Surface plasmon resonance (SPR)
    • 5.4.1.2 Bio-layer interferometry (BLI)
    • 5.4.1.3 Isothermal titration calorimetry (ITC)
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Microfluidics
    • 5.4.2.2 Artificial intelligence (AI)
    • 5.4.2.3 Optical coherence tomography (OCT)
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Mass spectrometry
    • 5.4.3.2 Flow cytometry
    • 5.4.3.3 Confocal microscopy
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PRICING ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 LABEL-FREE DETECTION MARKET: ROLE OF RAW MATERIAL SUPPLIERS
  • 5.8.2 LABEL-FREE DETECTION MARKET: ROLE OF MANUFACTURERS
  • 5.8.3 LABEL-FREE DETECTION MARKET: ROLE OF END USERS
  • 5.8.4 LABEL-FREE DETECTION MARKET: ROLE OF REGULATORY BODIES
• 5.9 PATENT ANALYSIS
  • 5.9.1 PATENT METHODOLOGY
  • 5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014-2023
  • 5.9.3 INNOVATION & PATENT APPLICATIONS
  • 5.9.4 TOP APPLICANTS
• 5.10 KEY CONFERENCES & EVENTS IN 2024-2025
• 5.11 REGULATORY LANDSCAPE
  • 5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.11.2 REGULATORY SCENARIO
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 THREAT OF NEW ENTRANTS
  • 5.12.2 THREAT OF SUBSTITUTES
  • 5.12.3 BARGAINING POWER OF BUYERS
  • 5.12.4 BARGAINING POWER OF SUPPLIERS
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA FOR LABEL-FREE DETECTION PRODUCTS
• 5.14 INVESTMENT & FUNDING SCENARIO
• 5.15 IMPACT OF AI ON LABEL-FREE DETECTION MARKET
• 5.16 TRADE ANALYSIS

6 LABEL-FREE DETECTION MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 INSTRUMENTS
  • 6.2.1 TECHNOLOGICAL ADVANCEMENTS IN LABEL-FREE DETECTION SYSTEMS TO DRIVE INSTRUMENTS MARKET
• 6.3 CONSUMABLES
  • 6.3.1 BIOSENSOR CHIPS
    • 6.3.1.1 High specificity and need for real-time monitoring of molecular interactions to drive adoption
  • 6.3.2 MICROPLATES
    • 6.3.2.1 Low cost to propel adoption among research laboratories and academic institutes
  • 6.3.3 REAGENTS & KITS
    • 6.3.3.1 Availability of ready-to-use kits for assay development to drive market
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 AUTOMATION BENEFITS IN LABEL-FREE DETECTION TO SUPPORT DEMAND GROWTH

7 LABEL-FREE DETECTION MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 SURFACE PLASMON RESONANCE
  • 7.2.1 GROWING USE OF SPR TECHNOLOGY IN AFFINITY AND KINETIC STUDIES TO FUEL MARKET GROWTH
• 7.3 DIFFERENTIAL SCANNING CALORIMETRY
  • 7.3.1 WIDE USAGE IN DRUG DISCOVERY AND DEVELOPMENT FOR PROTEIN CHARACTERIZATION TO DRIVE MARKET
• 7.4 BIO-LAYER INTERFEROMETRY
  • 7.4.1 MICROFLUIDICS-FREE NATURE OF BLI TO DRIVE MARKET
• 7.5 ISOTHERMAL TITRATION CALORIMETRY
  • 7.5.1 RISING USE IN LABEL-FREE MEASUREMENT OF BINDING AFFINITY AND THERMODYNAMICS TO PROPEL MARKET GROWTH
• 7.6 OTHER TECHNOLOGIES

8 LABEL-FREE DETECTION MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 BINDING KINETICS
  • 8.2.1 BINDING KINETICS TO HOLD LARGEST MARKET SHARE
• 8.3 BINDING THERMODYNAMICS
  • 8.3.1 WIDE USAGE IN BASIC RESEARCH FOR DRUG MECHANISM ANALYSIS TO SUPPORT MARKET GROWTH
• 8.4 HIT CONFIRMATION
  • 8.4.1 BENEFITS OVER OTHER APPROACHES FOR HTS TO DRIVE ADOPTION OF LABEL-FREE TECHNOLOGY
• 8.5 LEAD GENERATION
  • 8.5.1 DATA GENERATION CAPABILITIES IN DRUG CANDIDATE SELECTION PROCESS TO SUPPORT DEMAND
• 8.6 ENDOGENOUS RECEPTOR DETECTION
  • 8.6.1 HIGH SENSITIVITY OF LABEL-FREE ASSAYS TO PROPEL USAGE
• 8.7 OTHER APPLICATIONS

9 LABEL-FREE DETECTION MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 GROWING ADOPTION OF LFD TECHNOLOGIES TO FUEL MARKET GROWTH
• 9.3 ACADEMIC & RESEARCH INSTITUTES
  • 9.3.1 RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR RESEARCH TO DRIVE MARKET
• 9.4 CONTRACT RESEARCH ORGANIZATIONS
  • 9.4.1 INCREASING PHARMACEUTICAL OUTSOURCING TO DRIVE MARKET GROWTH
• 9.5 OTHER END USERS

10 LABEL-FREE DETECTION MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICA: MACROECONOMIC ANALYSIS
  • 10.2.2 US
    • 10.2.2.1 US to dominate North American label-free detection market during study period
  • 10.2.3 CANADA
    • 10.2.3.1 Increasing government support and funding for life science research to promote market growth
• 10.3 EUROPE
  • 10.3.1 EUROPE: MACROECONOMIC ANALYSIS
  • 10.3.2 GERMANY
    • 10.3.2.1 Increasing public and private funding for advanced cell-based research to drive market
  • 10.3.3 UK
    • 10.3.3.1 Increasing R&D spending by government and pharmaceutical companies to fuel market growth
  • 10.3.4 FRANCE
    • 10.3.4.1 Rising government healthcare investments and increasing focus on genomic medicine research to aid market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Increased focus on healthcare research and rising funding for new drug development to propel market growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Rising focus on personalized and translational medicine development to drive market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC: MACROECONOMIC ANALYSIS
  • 10.4.2 CHINA
    • 10.4.2.1 Improved medical service quality and growth in biopharmaceutical sector to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 High R&D expenditure and improved healthcare access to stimulate market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing R&D spending by pharmaceutical companies and growing government initiatives to drive market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Strategic geographical location and favorable regulatory environment to augment market growth
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Technological advancements and high healthcare spending to boost market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 LATIN AMERICA: MACROECONOMIC ANALYSIS
  • 10.5.2 BRAZIL
    • 10.5.2.1 Increased incidence of chronic diseases and improved public access to modern healthcare facilities to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Favorable trade agreements and government initiatives to spur market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MIDDLE EAST: MACROECONOMIC ANALYSIS
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Saudi Arabia
      • 10.6.2.1.1 Growing healthcare expenditure and increasing research institutes to boost market growth
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Adoption of advanced label-free detection products for research to aid market growth
    • 10.6.2.3 Rest of GCC Countries
  • 10.6.3 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 GROWING PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE MARKET
  • 10.7.2 AFRICA: MACROECONOMIC ANALYSIS

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN THE LABEL-FREE DETECTION MARKET
• 11.3 REVENUE SHARE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Offering footprint
    • 11.5.5.3 Technology footprint
    • 11.5.5.4 Application footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES/ENHANCEMENTS/UPGRADES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 DANAHER CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Expansions
      • 12.1.1.3.2 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 SARTORIUS AG
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches/enhancements/upgrades
      • 12.1.2.3.2 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 AGILENT TECHNOLOGIES, INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches/enhancements/upgrades
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 WATERS CORPORATION
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches/enhancements/upgrades
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 CORNING INCORPORATED
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches/enhancements/upgrades
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 REVVITY, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Other developments
  • 12.1.7 AMETEK, INC.
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
  • 12.1.8 HORIBA, LTD.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
  • 12.1.9 SPECTRIS
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches/enhancements/upgrades
      • 12.1.9.3.2 Deals
  • 12.1.10 SHIMADZU CORPORATION
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
  • 12.1.11 HITACHI HIGH-TECH CORPORATION
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 ATTANA AB
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 BRUKER
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches/enhancements/upgrades
  • 12.1.14 BIO-RAD LABORATORIES, INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
  • 12.1.15 ENDRESS+HAUSER GROUP SERVICES AG
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Expansions
  • 12.1.16 BECTON, DICKINSON AND COMPANY
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Product launches/enhancements/upgrades
• 12.2 OTHER PLAYERS
  • 12.2.1 NANOTEMPER TECHNOLOGIES GMBH
  • 12.2.2 AFFINITE INSTRUMENTS
  • 12.2.3 BIOSENSING INSTRUMENT
  • 12.2.4 UNCHAINED LABS
  • 12.2.5 BIONAVIS LTD.
  • 12.2.6 GATOR BIO
  • 12.2.7 CARTERRA, INC.
  • 12.2.8 NICOYA
  • 12.2.9 BIOPTIX ANALYTICAL LLC
  • 12.2.10 PLEXERA BIOSCIENCE
  • 12.2.11 XANTEC BIOANALYTICS GMBH
  • 12.2.12 BMG LABTECH
  • 12.2.13 REDSHIFT BIOANALYTICS, INC.
  • 12.2.14 LINO BIOTECH AG

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATIONS OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS